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Glioblastomas frequently express oncogenic EGFR and loss of the Ink4a/Arf locus. Bmi1, a posi-
tive regulator of stem cell self renewal, may be critical to drive brain tumor growth. In this issue of 
Cancer Cell, Bruggeman and colleagues suggest that brain tumors with these molecular alterations 
can be initiated in both neural precursor and differentiated cell compartments in the absence of Bmi1; 
however, tumorigenicity is reduced, and tumors contain fewer precursor cells. Surprisingly, tumors 
appear less malignant when initiated in precursor cells. Bmi1-deficient tumors also had fewer neuronal 
lineage cells, suggesting a role for Bmi1 in determination of cell lineage and tumor phenotype.Glioblastomas remain among the 
most aggressive human cancers. The 
application of the conceptual and 
methodological framework of neu-
ral stem cell biology to brain cancer 
(Bachoo et al., 2002; Holland et al., 
1998) and the identification of human 
brain tumor initiating cells (Singh 
et al., 2004) has opened up fresh 
approaches to interrogate the cell of 
origin for brain tumors. Particularly in 
mouse model systems, investigators 
can address the effect of expression 
of oncogenes or loss of tumor sup-
pressors in normal precursor or dif-
ferentiated cell compartments.
Current understanding of the mech-
anisms of tumor progression and ini-
tiation remain limited, particularly the 
cell context of recognized molecular 
signaling pathways implicated in the 
disease, such as aberrant EGFR sig-
naling. Does oncogene expression 
drive a stem cell or a progenitor com-partment in the tumor? Determinants 
of tumor phenotype and relationship 
to prognosis are also poorly under-
stood. How do distinct molecular 
alterations specify the ultimate histo-
pathologic tumor picture? How does 
the expression of neural precursor or 
differentiated lineages in the tumor 
correlate with tumor behavior? Are 
tumors that express more markers 
of differentiation less aggressive? As 
well, the relationship of tumor behav-
ior to the putative cell of origin is not 
understood. Do tumors arise in a 
stem cell or a more differentiated cell 
compartment, and does the behavior 
and phenotype of the tumor depend 
on the cell compartment of origin? 
Are tumors that arise in stem cell 
compartments more malignant than 
those arising in progenitors, or vice 
versa? These questions come in to 
focus in the study by Bruggeman and 
colleagues (Bruggeman et al., 2007).Cancer Cell 12Bmi1 has been implicated in con-
trol of stem cells in multiple tissues, 
particularly as a positive regulator of 
self renewal, and Bmi1-deficient mice 
have deficiencies in their stem cell 
compartments, including the brain 
(Molofsky et al., 2003; Park et al., 
2003). Bmi1 promotion of proliferation 
and self renewal is thought to relate 
to suppression of the Ink4a/Arf locus 
(Bruggeman et al., 2005), although 
other loci have recently been shown 
to be targeted as well (Fasano et al., 
2007). Ink4a/Arf loss itself, consistent 
with its tumor suppressor role, causes 
increased neural stem cell activity in 
vivo (Molofsky et al., 2006). Although 
Ink4a/Arf is lost genetically in a large 
fraction of human glioblastoma sam-
ples, mice deficient for Ink4a/Arf rarely 
develop spontaneous brain tumors.
The current study by Bruggeman 
et al. (2007) attempts to further probe 
the functional role of Bmi1 together , October 2007 ©2007 Elsevier Inc. 295
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vivo oncogenic transduction 
model of glioma. Are tumors 
that can be initiated in the 
context of Ink4a/Arf defi-
ciency dependent on Bmi1?
The authors transduced 
either mouse adult-derived 
adherent neural precursor 
cells or early postnatal (day 
7)-derived cortical mouse 
astrocytes with a brain 
tumor-associated oncogene 
to test the effects of tumori-
genicity in the presence of a 
Bmi1-deficient background. 
The main finding of this study 
is that in the presence of 
Ink4a/Arf and Bmi1 defi-
ciency, transformation by 
oncogenic EGFR results in 
different growth kinetics and 
tumor cell lineages depend-
ing on whether neural pre-
cursor cells or astrocyte cells 
are transformed. Importantly, 
both cell compartments are 
permissive for transforma-
tion, and therefore, Bmi1 
expression is not required 
for tumor initiation. How-
ever, loss of Bmi1 attenuates 
overall tumorigenicity (in 
both cell compartments) in 
an Ink4a/Arf-deficient back-
ground and also affects lin-
eage determination in result-
ing tumors; Bmi1 seems to 
be required for specification 
of neuronal lineages in the 
resulting tumors. In addition, 
Bmi1-deficient tumors have 
fewer cells expressing the neural pre-
cursor marker nestin, suggesting that 
one reason they may be less aggres-
sive is that they have fewer stem cells. 
It remains uncertain whether in vivo 
tumors that lack Bmi1 are critically 
impaired in their self renewal ability, as 
defined by serial transplantation stud-
ies (Lessard and Sauvageau, 2003).
The results suggest most strongly 
that the brain tumors that emerge in 
these models depends on the cell 
context, and perhaps surprisingly, 
tumors originating from cultures 
highly enriched for neural stem cells 
appear less malignant than those 
arising from astrocytes, although 
mice died at about the same time 
(Figure 1). As normal neural stem 
cells are thought to be predomi-
nantly quiescent in vivo, could 
transformation events in these cells 
cause a more slowly proliferating 
(although not shown here) and less 
aggressive tumor?
These findings are very interesting, 
but there are questions concerning 
the purity of cell types that are trans-
formed, which reflects our generally 
poor understanding of the normal 
neural stem cell hierarchy and pos-
sible problems with cultures. The 
normal neural stem cell hier-
archy is largely undefined, 
and a paucity of cell surface 
markers makes progress 
challenging. The markers 
used to identify cell popula-
tions in the brain are also not 
specific; GFAP marks stem 
cells as well as differentiated 
astrocytes. Consequently, 
the populations tested for 
transformation ability in 
this study are not directly 
purified from the brain but 
are derived from cultures, 
which may alter the func-
tion of the stem cells and 
more differentiated cells. 
The precursor and differen-
tiated populations are not 
matched for age; could the 
astrocyte cultures derived 
from P7 brain contain more 
primitive cells than the 
adult derived precursors? 
Also, the effect that Bmi1 
deficiency has on the nor-
mal neural stem cell com-
partment suggests that the 
starting cell populations in 
wild-type versus the defi-
cient Bmi1 cells may be dif-
ferent. Despite these con-
cerns, the authors do use 
state-of-the-art techniques 
to obtain enriched popula-
tions of stem cells or differ-
entiated cells.
This study also suggests 
that Bmi1 may have a role 
outside control of neu-
ral stem cells in the brain. 
Bmi1 is widely expressed in the 
postnatal brain, and it is expressed 
in the bulk population of the human 
brain tumor samples. This data 
would suggest that Bmi1 has a 
functional role in both normal stem 
cells and differentiated cells of the 
brain or different functions in these 
distinct cell populations. Bmi1 may 
be important for specifying differen-
tiated neuronal lineages in the brain 
as shown by data in vitro and in the 
tumors in vivo.
In summary, these studies, which 
are challenging to perform, raise 
further interesting questions about 
figure 1. Tumor Phenotype Depends on Bmi1 status and 
cell of Origin
(A) Neural stem cells self renew and generate differentiated cell types. 
It remains unclear which cell in the normal stem cell hierarchy is the 
cell of origin for brain tumors. Tumors of distinct phenotypes could 
have different cells of origin.
(B) The effect of transformation of cultures of neural precursor cells 
enriched for stem cells versus differentiated astrocytes was tested. 
Astrocytes deficient in Ink4a/Arf that are transformed with oncogenic 
EGFR give rise to malignant glioblastoma-like tumors. In the absence 
of Bmi1, mice survive longer, and their tumors have few nestin+ cells 
and few neuronal lineage+ cells. In contrast, neural precursors, trans-
formed with the identical mechanisms, give rise to tumors that showed 
less-malignant features. Although mice died from their tumors, those 
with an absence of Bmi1 lived longer, had fewer nestin+ cells, and few 
neuronal lineage+ cells.296 Cancer Cell 12, October 2007 ©2007 Elsevier Inc.
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that play a role in brain tumors and 
do provide important further insight 
into the role of Bmi1 in brain tumori-
genesis. The finding that distinct 
tumor phenotypes that arise from 
transformation of different cell 
populations in the brain suggests 
that knowing the cell of origin may 
be important for understanding the 
prognosis of the tumor. It will likely 
also be important to determine the 
signaling mechanisms that subse-
quently become operational in the 
different cell contexts to devise new 
therapies.One of the most successful examples 
of targeted therapies for epithelial 
cancers has been the demonstration 
that breast cancers with amplifica-
tion of the ERBB2/HER2 oncogene 
are responsive to trastuzumab (Her-
ceptin), a humanized monoclonal 
antibody directed against the trans-
membrane HER2 protein. As a result, 
patients whose breast cancer cells 
demonstrate overexpression of HER2 
protein by immunohistochemistry 
and/or gene amplification by fluores-
cence in situ hybridization (FISH) are 
PI3 Kinase Activ
to Trastuzumab 
with Herceptin R
Ben Ho Park1 and Nancy E. Davidson
1Breast Cancer Program, The Sidney Kimm
MD 21231, USA
*Correspondence: davidna@jhmi.edu
DOI 10.1016/j.ccr.2007.10.004
Trastuzumab is an established t
Despite its proven benefit in trea
clonal antibody, and resistant dis
evidence that activation of the PI
through oncogenic stimulation of
important work of others and form
PI3 kinase pathway in conjunctioRefeRences
Bachoo, R.M., Maher, E.A., Ligon, K.L., Sharp-
less, N.E., Chan, S.S., You, M.J., Tang, Y., De-
Frances, J., Stover, E., Weissleder, R., et al. 
(2002). Cancer Cell 1, 269–277.
Bruggeman, S.W., Valk-Lingbeek, M.E., van der 
Stoop, P.P., Jacobs, J.J., Kieboom, K., Tanger, 
E., Hulsman, D., Leung, C., Arsenijevic, Y., Mari-
no, S., and van Lohuizen, M. (2005). Genes Dev. 
19, 1438–1443.
Bruggeman, S.W.M., Hulsman, D., Tanger, E., 
Buckle, T., Blom, M., Zevenhoven, J., van Tell-
ingen, O., and van Lohuizen, M. (2007) Cancer 
Cell, this issue.
Holland, E.C., Hively, W.P., DePinho, R.A., and 
Varmus, H.E. (1998). Genes Dev. 12, 3675–
3685.Cancer Cell 12
candidates for this therapy in both 
the adjuvant and metastatic settings 
(reviewed in Hudis, 2007). However, 
as with many cancer therapies, not 
all women whose tumors overex-
press HER2 will respond to trastu-
zumab. Indeed, only about one-third 
of women with newly diagnosed 
advanced breast cancer that over-
expresses HER2 demonstrate tumor 
regression with trastuzumab mono-
therapy (Vogel et al., 2002). Also, 
trastuzumab treatment is not without 
cost in both economic and human 
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terms. Although it is generally well 
tolerated, rare but significant car-
diac toxicity can develop in patients 
receiving this therapy, especially 
when it is given in close proximity 
to anthracycline chemotherapy. One 
year of trastuzumab therapy, the cur-
rent standard regimen in early breast 
cancer, costs approximately $50,000 
(USD). Therefore, the identification of 
predictive biomarkers that can more 
accurately select responders or non-
responders is vital to improve the 
therapeutic index of this agent. Also, 
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